B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of long-lived mature B cells with the distinctive phenotype CD19 hi CD5 + CD23 + IgM lo , which are refractory to apoptosis. An increased level of apoptosis has been observed on treatment of human B-CLL cells with protein kinase C (PKC) inhibitors, suggesting that this family of protein kinases mediate survival signals within B-CLL cells. Therefore, to investigate the ability of individual PKC isoforms to transform developing B cells, we stably expressed plasmids encoding PKC mutants in fetal liver-derived hematopoietic progenitor cells (HPC) from wild-type mice and then cultured them in B-cell generation systems in vitro and in vivo. Surprisingly, we noted that expression of a plasmid-encoding dominant-negative PKCA (PKCA-KR) in HPCs and subsequent culture both in vitro and in vivo resulted in the generation of a population of cells that displayed an enhanced proliferative capacity over untransfected cells and phenotypically resemble human B-CLL cells. In the absence of growth factors and stroma, these B-CLL-like cells undergo cell cycle arrest and, consistent with their ability to escape growth factor withdrawal-induced apoptosis, exhibited elevated levels of Bcl-2 expression. These studies therefore identify a unique oncogenic trigger for the development of a B-CLL-like disease resulting from the subversion of PKCA signaling. Our findings uncover novel avenues not only for the study of the induction of leukemic B cells but also for the development of therapeutic drugs to combat PKCA-regulated transformation events.
Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in the Western world and can be characterized by an accumulation of long-lived mature B cells with the distinctive phenotype CD19
hi CD5 + CD23 + IgM lo , which are refractory to apoptosis and have undergone cell cycle arrest in the G 0 -G 1 phase (1) . A variety of mechanisms have been shown to account for the clonal expansion of this leukemic population of B cells, including chromosomal abnormalities and intrinsic defects in their apoptosis machinery due to both higher levels of the antiapoptotic protein Bcl-2 family member proteins and aberrations of the p53 tumor suppressor gene (1, 2) . Notably, treatment of human B-CLL cells with protein kinase C (PKC) and phosphatidylinositol 3-kinase inhibitors leads to increased levels of apoptosis (3) (4) (5) (6) , suggesting that these protein kinases may mediate survival signals within B-CLL cells.
PKC represents a family of closely related serine/threonine protein kinases that share structural features and requirements for Ca 2+ , phospholipid, and diacylglycerol (7) . PKCs are divided into three subfamilies, classic Ca 2+ -dependent isoforms (a, hI/II, g), novel Ca 2+ -independent isoforms (y, q, D, u), and atypical isoforms (~,E/L; ref. 7) . PKC regulates key biological events, including proliferation, differentiation, cell survival, and gene transcription in response to diverse stimuli (8) . To execute these cellular processes, PKC is regulated by, and functionally interacts with, several protooncogenes, such as phosphoinositide-dependent kinase 1, Ras, Raf-1, and Bcl-10, which are key regulators of Akt/protein kinase B, mitogen-activated protein kinase, and nuclear factor-nB signaling pathways involved in the survival and proliferation of B cells (9) (10) (11) (12) (13) . Therefore, it is perhaps unsurprising that dysregulation of specific PKC isoforms, particularly PKCa, have been implicated in a diverse range of cancers (14) . Indeed, PKCa has become a focus for potential therapies with the use of antisense oligonucleotides, small interfering RNA, and PKC inhibitors in a range of cancer types (6, (15) (16) (17) .
In an effort to address the potential role of specific PKC isoforms during B-cell transformation, we stably expressed PKC mutants in fetal liver-derived hematopoietic progenitor cells (HPC) from wildtype mice using retrovirally mediated techniques and then tested the ability of these constructs to transform developing B lymphocytes (18, 19) . Our studies reveal that disruption of PKCa signaling by the expression a dominant-negative PKCa construct in HPCs results in the spontaneous development of a B-CLL-like population both in vitro and in vivo.
green fluorescent protein (GFP; ref. 21) . The dominant-negative PKC isoforms were generated by introducing a point mutation at the lysine in the ATP-binding domain of each PKC isoform as follows: PKCa, PKCa-KR(K 368 R) and PKCy, PKCy-KR(K 376 R) (18, 22) . A constitutively active form of PKCa (PKCa-CAT) was generated by deleting the regulatory NH 2 -terminal domain of PKCa (18) . A hemagglutinin (HA) tag was engineered onto the COOH-terminal of each PKC construct to allow confirmation of expression at the protein level using an anti-HA antibody (18) . The retroviral vectors were stably expressed in the retroviral packaging line, GP+E.86 (21, 23) . OP9 is a bone marrow stromal cell line derived from op/op mice, which are deficient in macrophage colony-stimulating factor (M-CSF; ref. 19) .
Retroviral infection of HPC-enriched cell populations. HPC-enriched fetal liver cells derived from wild-type ICR mice were prepared as described previously (24) and cocultured with the mitomycin C-treated retroviral packaging line in complete medium [high-glucose DMEM containing 13% fetal bovine serum (BioWhittaker UK Ltd., Wokingham, United Kingdom), 100 units/mL penicillin, 100 Ag/mL streptomycin, 2 mmol/L glutamine, 1 mmol/L sodium pyruvate, 10 mmol/L HEPES, 50 Amol/L 2-mercaptoethanol (2-ME), and 10 Ag/mL gentamicin (Invitrogen, Paisley, United Kingdom)] supplemented with 500 Ag/mL polybrene (Sigma-Aldrich Co., Poole, United Kingdom) and 10 ng/mL cytokines [interleukin (IL)-6, IL-7, and stem cell factor (SCF); PeproTech EC Ltd., London, United Kingdom] for 24 to 48 before being placed in either an in vitro B-cell generation system or adoptively transferred into RAG-1 À/À mice.
B-cell generation in vitro.
To analyze the ability of retrovirally infected HPC populations to develop into mature B lymphocytes in vitro, the cells were removed from the retroviral packaging lines and cocultured with OP9 cells (19) in the presence of IL-6, IL-7, and SCF (10 ng/mL of each; 20,000 cells per well of a six-well plate). The developing cells were removed from the OP9 layer by gentle pipetting and placed onto a fresh layer of OP9 cells in the presence of 10 ng/mL IL-7 only once every 5 to 7 days. Cells were removed for analysis as indicated in the figure legends.
Flow cytometric analysis. R-phycoerythrin (PE)-conjugated, allophycocyanin (APC)-conjugated, and biotin-conjugated anti-mouse antibodies were used for flow cytometric analysis (BD Biosciences, Oxford, United Kingdom). Cell samples were prepared for fluorescence-activated cell sorting (FACS) analysis as described previously (24) . The cells were acquired on a FACSCalibur flow cytometer using the CellQuest software package (BD Biosciences) to acquire and the FlowJo software package (Tree Star, Inc., Stanford, CA) to analyze the data. All data shown are live gated by size and lack of propidium iodide (PI; Sigma-Aldrich) uptake.
PKC activity assay. Cell samples were washed in ice-cold PBS twice and resuspended in ice-cold sample preparation buffer [30 mmol/L Tris-HCl (pH 7.0), 15 mmol/L NaCl, 5 mmol/L EGTA, 2.6 mmol/L EDTA, 25 mmol/L 2-ME, and 0.05% (v/v) Triton X-100 supplemented with Complete Protease Inhibitor Cocktail (Roche Diagnostics Ltd., Lewes, United Kingdom)]. Lysates were sonicated for 5 seconds five times and then centrifuged at 15,000 Â g for 60 minutes at 4jC. The supernatant was then collected and the protein concentration was determined using Bradford method (25) . Protein (10 Ag) was assayed per sample in triplicate. PKC activity was measured based on the phosphorylation of a PKC substrate peptide using a nonradioactive protein kinase assay according to the manufacturer's protocol (Calbiochem-Novabiochem Co., Darmstadt, Germany).
SDS-PAGE and Western blotting. Cell samples were removed from the OP9 cell line and either treated with phorbol ester [20 or 200 nmol/L 12-Otetradecanoylphorbol-13-acetate (TPA); Cell Signaling Technology, Hitchin, United Kingdom] for 30 minutes or left unstimulated as indicated in the figure legends. Thereafter, cell lysates (4 Ag/sample) were prepared, resolved, and transferred onto polyvinylidene difluoride membranes as described previously (24) . The level of phosphorylation of PKC substrates was detected using an anti-phosphoserine PKC substrate antibody (Cell Signaling Technology) followed by horseradish peroxidase-conjugated goat anti-rabbit IgG (Cell Signaling Technology). Blots were revealed using SuperSignal West Pico Chemiluminescent Substrate (Perbio, Tattenhall, United Kingdom; ref. 24) .
Cell cycle analysis. Cell samples were removed from the OP9 cell line 2 days before PI analysis and the dead cells were removed by density centrifugation over Lymphocyte-Mammal (VH Bio Ltd., Newcastle, United Kingdom) as described previously (24) . The cells were then resuspended in complete medium in the conditions described in the figure legends at a concentration of 2 Â 10 5 per well. Cellular DNA content was detected by PI staining. Cells were lysed in 0.2% Triton X-100-PBS solution and incubated for 10 minutes on ice. The lysed cells were treated with 0.5% RNase (SigmaAldrich) to remove RNA followed by the addition of PI to a final concentration of 50 Ag/mL (26) . PI incorporation was analyzed using a FACSCalibur flow cytometer using the CellQuest software package, with an activated doublet discriminator module, to acquire and the FlowJo software package to analyze the data.
Bromodeoxyuridine incorporation. Cell samples were removed from the OP9 cell line 2 days before analysis and the dead cells were removed by density centrifugation. The resultant cells were resuspended in complete medium in the conditions described in the figure legends at a concentration of 2 Â 10 5 per well. Bromodeoxyuridine (BrdUrd; 50 Amol/L) was added 23 hours before cell harvesting, at which time the cells were washed once in PBS and then fixed using the Cytofix/Cytoperm kit as described by the manufacturer (BD Biosciences). To expose incorporated BrdUrd, cells were washed in BD Perm/Wash solution and treated with DNase at the final concentration of 300 Ag/mL for 1 hour at 37jC and then stained with antiBrdUrd-APC antibody (1:300 dilution; BD Biosciences) for 20 minutes at 4jC. Cells were then resuspended in 7-actinomycin D to stain DNA and washed in the BD Perm/Wash solution, and the samples were acquired on a FACSCalibur flow cytometer using the CellQuest software package. All data shown were size gated by discrimination based on forward scatter and side scatter. FlowJo software package was used to analyze the data.
RNA purification and reverse transcription-PCR. RNA was isolated from HPC-OP9 cocultures throughout the culture period as indicated in the figure legends using the RNA-Easy RNA purification procedure (Qiagen, Crawley, United Kingdom). Semiquantitative PCR reactions were done using the same serially diluted cDNA batches shown for h2-microglobulin (h2m; ref. 24) . All PCR products correspond to the expected molecular sizes. Genespecific primers used for PCR are as follows: ;h2m_U: 5V-GGCGTCAA-CAATGCTGCTTCT-3V and h2m_L: 5V -CTTTCTGTGTTTCCCGCTCCC-3V (277 bp), Bcl-2_U: 5V -GGGAGAACAGGGTATGA-3V and Bcl-2_L: 5V-ATCTCTGCGAAGTCACG-3V (323 bp), and Bcl-X L _U: 5V-GAAGCAGAGAGG-GAGACC-3V and Bcl-X L _L: 5V -CTCCTTGTCTACGCTTTC-3V (351 bp).
Adoptive transfer of retrovirally infected HPCs into mice. To analyze the ability of retrovirally infected HPC populations to develop into mature lymphocytes in vivo, the cells were removed from the retroviral packaging lines, and after removal of the dead and nonlymphoid cells by density centrifugation over Lymphocyte-Mammal at 600 Â g for 15 minutes at room temperature, the cells were resuspended in PBS at a concentration of 1 Â 10 7 /mL and injected i.p. into neonatal RAG-1 À/À mice at a concentration of 1 Â 10 6 . The mice were sacrificed 2 to 5 weeks postinjection and the bone marrow, spleen, lymph node, and tumors were removed for analysis as indicated in the figure legends.
Results
HPCs exhibit a proliferative advantage on subversion of PKCA signaling. To determine the potential role of individual PKC isoforms to transform developing B cells, fetal liver-derived HPCs were prepared from wild-type mice and retrovirally infected with a plasmid encoding either vector control (MIEV) or dominantnegative PKCa (PKCa-KR) or PKCy (PKCy-KR) constructs (18) and then cocultured the cells with the bone marrow stromal cell line OP9 in the presence of growth factors, thus promoting the generation of B lymphocytes in vitro (19) . The retroviral vector (MIEV) enables the generation of a bicistronic message encoding the gene of interest (dominant-negative PKC isoform) coupled to GFP. Therefore, on stable integration into mouse fetal liver-derived HPCs, the retrovirally infected cells can be monitored using flow cytometry (21) . 1A ). This was in contrast to cocultures containing HPCs retrovirally infected with either MIEV or PKCy-KR, which maintained a relatively constant percentage of GFP expression (Fig. 1A) . The observed growth advantage of PKCa-KRexpressing GFP + cells was accompanied by substantial elevation in cell numbers compared with MIEV-and PKCy-KR-expressing cocultures. Indeed, PKCa-KR-expressing cells proliferate 1.5-fold more in a 24-hour period than MIEV-expressing cells. PI analysis confirmed that the relative elevation in cell number in PKCa-KR cocultures was not due to an increase in apoptosis in MIEV cocultures (data not shown).
To address whether the elevation in cell number in PKCa-KR (GFP + )-expressing cells was due to an enhanced proliferation, the cells were analyzed by BrdUrd incorporation to measure the level of DNA synthesis in the cell cultures (Fig. 1B) . This set of analysis was carried out on MIEV and PKCa-KR retrovirally infected HPCs after 12 days of culture as >90% of PKCa-KRexpressing coculture were GFP + at this stage ( Fig. 1A ; data not shown). It was noted that PKCa-KR-expressing cells possessed an increased proliferative capacity as shown by their ability to incorporate significantly more BrdUrd compared with MIEVexpressing cells (Fig. 1B) . Taken together, these results show that in the presence of stroma and growth factors the subversion of PKCa signals leads to an increase in the proliferative capacity of developing HPCs.
PKCA-KR-expressing cells display a decrease in PKC activity. To confirm that PKCa-KR and PKCy-KR expression could be correlated with GFP expression, we made use of the fact that a HA tag was fused to the COOH terminus of the PKC-KR constructs during the construction of the vector, thus allowing confirmation of expression of the exogenously added constructs at the protein level (18) . Flow cytometric analysis revealed that HA expression within each PKC-KR-expressing GP+E.86 packaging cell line correlated with the level of GFP expression, whereas the control MIEV-expressing cell line expressed high levels of GFP and background levels of HA ( Fig. 2A) . As expected, intracellular staining revealed that HPCs retrovirally infected with PKCa-KR exhibited a high expression of HA compared with MIEV control cells (Fig. 2B ).
An attenuation of PKC activity was observed in PKCa-KRexpressing cells compared with MIEV cells in both GP+E.86 packaging cell lines (Fig. 2C ) and HPC-OP9 cocultured cells (Fig. 2D) . Indeed, a 50% reduction in the kinase activity was observed in HPCs retrovirally infected with PKCa-KR compared with MIEV-expressing cells, showing a significant decrease in PKC activity in these cells (Fig. 2D) . Importantly, analysis of the kinase activity of a GP+E.86 packaging line stably expressing an established constitutively active form of PKCa mutant (PKCa-CAT; refs. 18, 21, 24) revealed an 34% elevation in kinase activity relative to MIEV-GP+E.86 cells (Fig. 2C) . In support of these findings, immunoblotting analysis revealed a decrease in the level of serine phosphorylation of downstream substrates of PKC in lysates derived from PKCa-KR-expressing HPCs compared with MIEV-expressing HPCs (Fig. 2E) . In addition, a reduction in the level of phosphorylation of PKC substrates was noted on TPA stimulation in PKCa-KR-expressing HPCs compared with MIEV control cells (Fig. 2E ). Taken together, these results show that an attenuation of PKCa signals leads to an increase in the proliferative capacity of developing HPCs.
Disruption of PKCA signaling results in the outgrowth of a B-CLL-like population in vitro. To define the phenotype of the retrovirally infected populations, flow cytometric analysis of the GFP + cells was carried out using cell surface markers that can define the developmental stages of B-cell maturation. As expected, >95% of the GFP + cocultured cells expressed the B-cell markers CD45R (B220) and CD19, establishing that the retrovirally infected cells had committed to the B-cell lineage ( Fig. 3; data not human B-CLL cells observed in PKCa-KR-expressing cultures, we also noted an elevation in CD2 levels compared with MIEV-or PKCy-KR-expressing cultures, thus broadening the B-CLL-like phenotype of the proliferating population in our in vitro mouse model system (Fig. 3 ). Molecular analysis of the immunoglobulin heavy chain locus in both MIEV and PKCa-KR cellular populations revealed that a similar pattern of multiple, random rearrangements occurred in both populations (data not shown; ref. 27). These results served to confirm that the proliferating PKCa-KR population arose from several distinct transformed progenitor cells. Therefore, these findings indicate that subversion of PKCa signaling in HPCs stimulates aberrant expansion of an oligoclonal population of developing B lymphocytes that resemble B-CLL. Subversion of PKCA signaling enables cells to evade apoptosis. One of the hallmarks of B-CLL is the accumulation of B lymphocytes that are arrested in the G 0 -G 1 phase of the cell cycle and are refractory to apoptosis (1, 28) . Therefore, to test whether the B-CLL-like cells were able to survive in the absence of both stroma and growth factors, we cultured MIEV or PKCa-KR retrovirally infected cells in the absence of both IL-7 and OP9 after 12 days in culture. Our results show that B lineage cells expressing PKCa-KR were able to survive under these conditions, whereas the majority of control (MIEV) cells were dead after 3 days in such cultures (Fig. 4A) . These results established that the B-CLLlike cells generated on expression of PKCa-KR displayed a survival advantage over control cells. This finding was confirmed by carrying out PI analysis, which revealed that >3-fold more cells died in the control cell culture on withdrawal of stroma and growth factors compared with PKCa-KR-expressing cells, indicating that the cells were able to evade apoptosis (Fig. 4B) . Moreover, the majority of PKCa-KR-expressing cells were halted in the G 0 -G 1 phase of the cell cycle, a hallmark of B-CLL in vivo (Fig. 4B) .
Bcl-2 has long been reported to be a causative factor in the increased survival rate of B-CLL cells (1, 29) . Therefore, to gain an understanding of the mechanism by which the B-CLL-like population modulates apoptotic/survival rates, we analyzed the expression levels of the antiapoptotic factors Bcl-2 and Bcl-X L in control and PKCa-KR-expressing cells during in vitro cultures (1, 29) . This analysis revealed that although Bcl-2 transcript levels were down-regulated at day 14 in control cultures they remained elevated in PKCa-KR-expressing cells, a characteristic of B-CLL (Fig. 4C) . Indeed, when normalized to h2m expression, the expression levels of Bcl-2 were f4-fold higher than that of MIEV-derived samples at day 14 (Fig. 4C ). In contrast, the level of Bcl-X L transcripts remained unchanged in both control and PKCa-KR-expressing cultures (Fig. 4C) . Collectively, these studies provide a causal link between the subversion of PKCa signaling in developing B lymphocytes and the generation a transformed population of cells resembling human B-CLL that can escape apoptosis via a process that likely involves the up-regulation Bcl-2.
Inhibition of PKCA signaling in HPCs results in the generation of a B-CLL-like population in vivo. To test the impact of the stable expression of PKCa-KR in vivo, retrovirally infected fetal liver HPCs were adoptively transferred into RAG-1 À/À mice, which lack mature B and T lymphocytes (20) . The ability of wild-type donor cells to reconstitute lymphoid organs of host RAG-1 À/À mice was assessed by analyzing the spleen and lymph nodes 2 to 4 weeks postinjection. Notably, flow cytometric analysis of spleen and lymph node samples revealed an increase in the Figure 2 . PKCa-KR-expressing cells display a decrease in PKC activity. A, cell suspensions of MIEV, PKCa-KR, and PKCy-KR-GP+E.86 retroviral packaging lines were analyzed by flow cytometry for the expression of GFP or fixed, permeabilized, and stained with an anti-HA antibody, which reveals the retrovirally introduced PKCa-KR or PKCy-KR construct by virtue of the HA tag engineered to the 5V end of the construct. B, HPC-enriched fetal liver cells were prepared from wild-type mice and retrovirally infected with MIEV or PKCa-KR and then seeded on OP9 cells in the presence of growth factors and cultured for 16 days. PKCa-KR expression was determined by fixing and permeabilizing the cells, before staining with an anti-HA antibody, to reveal the retrovirally introduced PKCa-KR construct. C, lysates were prepared from MIEV, PKCa-KR, and PKCa-CAT-GP+E.86 retroviral packaging lines and PKC activity was assessed. Columns, % kinase activity relative to MIEV-GP+E.86 control cells (100%); bars, SE. D, lysates were prepared from MIEV and PKCa-KR retrovirally infected cells that were cultured as described above, before the determination of PKC activity. Columns, % kinase activity relative to MIEV fetal liver control cells (100%); bars, SE. E, MIEV and PKCa-KR retrovirally infected cells cultured as described above were incubated in the presence or absence of phorbol ester (0, 20, or 200 nmol/L TPA as indicated). Lysates were prepared and resolved by SDS-PAGE under reducing conditions and subsequently immunoblotted with a specific antibody against phosphoserine PKC substrates. (Table 1 ; data not shown). This suggests that PKCa-KR-expressing cells display an elevated proliferative potential in vivo and supports our in vitro data (Fig. 1) . This notion was supported by the finding that a reduction in the percentage of GFP + HPCs in the MIEV sample before injection resulted in a reduction in the percentage of GFP + cells recovered from the reconstituted spleen (Table 1) .
Phenotypic analysis revealed that, as expected, a population of mature B lymphocytes was present in the GFP À populations of both MIEV-and PKCa-KR-injected mice ( Fig. 6A ; data not shown). It has been shown previously that the level of gene expression in bicistronic retroviral vectors can be directly related to the intensity of GFP expression ( Fig. 2A; refs. 21, 24) ; therefore, it is interesting to note that the expression levels of CD23, CD19, and CD5 were elevated with increasing GFP expression in the s.c. tumors. This was shown by comparing the MFI for specific cell surface markers on B lineage cells in PKCa-KR GFP lo compared with GFP hi populations: CD19 (98.0 versus 99.2), CD23 (90.1 versus 172), and CD5 (23.2 versus 66.7; Fig. 6A ). Additionally and in agreement with our previous in vitro and in vivo data, IgM expression was down-regulated on the tumor cells with increasing GFP expression levels (16.2 versus 11.6; Fig. 6A ). This finding suggests that the frequency of B-CLL cells increases with elevating levels of PKCa-KR expression in vivo (Fig. 6A) .
This highly enriched population of B-CLL cells provided us with an ideal opportunity to analyze the cell cycle profile of in vivo-generated B-CLL cells. PI analysis revealed that tumor cells isolated fresh ex vivo were almost entirely arrested in the G 0 -G 1 phase of the cell cycle (Fig. 6B) , therefore bearing a striking similarity to the B-CLL cells isolated from humans (1, 28) . Culture of these tumor-derived cells fresh ex vivo in the absence of both growth factors and stroma resulted in cell death, a finding that is common in B-CLL cells isolated from patients (data not shown). To determine whether the tumor cells could be induced to proliferate, therefore overcoming the cell cycle arrest, the tumor cells were seeded onto OP9 in the presence of growth factors and the cell cycle profile was determined after 5 days in culture. PI analysis revealed that the tumor cells reentered cell cycle (Fig. 6B) , suggesting that although these cells were generated in vivo they maintain the ability to reenter the cell cycle when introduced into the proliferative conditions of the in vitro cocultures.
Collectively, our results establish that the disruption of PKCa signaling acts as an oncogenic trigger for developing B lymphocytes resulting in the generation of transformed cells that bear many of the key hallmarks of B-CLL both in vitro and in vivo.
Discussion
In this article, we present novel data showing that attenuation of PKCa signaling in mouse HPCs results in the spontaneous generation of a population of cells that resembles human B-CLL at the level of (a) phenotype (CD19 hi CD5 + CD23 + IgM lo ), (b) cell cycle phase (halted in G 0 -G 1 ex vivo), and (c) resistance to apoptosis (possibly due to an elevation in Bcl-2 expression). Moreover, we show that during the initiation of transformation PKCa-KRexpressing HPCs possess an enhanced proliferative capacity both in vitro and in vivo, potentially reflecting the dynamic cellular kinetics that exist during the progression of human B-CLL (31) . Our data establish an important link between PKCa and B-CLL and provide an excellent model system to study the cellular and molecular mechanisms that drive the induction of B-CLL, therefore engendering the possibility of novel therapeutic avenues.
Whereas our results reveal that a B-CLL-like population of cells develops on stable expression of dominant-negative PKCa, studies using the PKCa À/À mouse model show that a lack of PKCa activity does not result in the development of spontaneous cancers, suggesting that PKCa does not normally behave as a tumor suppressor (32) . This is in contrast to recent studies establishing that the Ras-GTPase-activating protein-associated docking proteins Dok-1 and Dok-2 act as tumor suppressors of chronic myelogenous leukemia (CML) as shown by the development of CML in Dok-1 (33, 34) . In addition, reports require expression of the pre-BCR, whereas it seems that the induction of B-CLL by subversion of PKCa signaling can occur independently of pre-BCR expression. Indeed, a B-CLL-like population of cells can be generated on introduction of PKCa-KR into HPCs derived from RAG À/À mice, which lack the ability rearrange the heavy chain locus and are therefore blocked in development before the expression of a pre-BCR complex (20) . 4 Although knockout mouse models have highlighted the importance of PKCh and PKC~in controlling B-cell activation, survival, and proliferation (38) (39) (40) and PKCy in mediating B-cell tolerance (41, 42) , none of these models identify specific roles for individual PKC isoforms during early B-cell maturation, suggesting a functional redundancy exists between PKC family members (7). Interestingly, B lymphocytes from PKCy À/À mice display splenomegaly and lymphadenopathy due to increases in the numbers of peripheral B cells (41, 42) ; therefore, it is perhaps surprising that HPCs expressing PKCy-KR do not display a growth advantage in our B-cell generation systems. However, PKCy À/À mouse-derived mature B cells proliferate because they are unable to undergo B-cell anergy in response to self-antigen (41, 42) . Therefore, lack of proliferation observed in PKCy-KR retrovirally infected cells may be due to an absence of antigen in our in vitro HPC-OP9 coculture system (43).
Our results indicate that retroviral infection of HPCs with a plasmid encoding dominant-negative PKCa induces the transformation of B lymphocytes in vivo and in vitro. The fact that our system revealed the transformation specifically of B lymphocytes is perhaps unsurprising, as our in vitro B-cell generation system uses the stromal cell line, OP9, derived from op/op mice, which are deficient in M-CSF (19) . OP9 cells support hematopoiesis and lymphopoiesis from HSCs, but the lack of M-CSF expression contributes to the preferential development of B lymphocytes over macrophages (19) . Our previous results suggest that expression of PKCa-KR does not trigger oncogenesis in developing T lymphocytes (21) ; however, it remains to be established whether subversion of PKCa signaling can generate an oncogenic signal in other hematopoietic cell lineages, such as natural killer lymphocytes, macrophages, or granulocytes, as has been established for several other cell types (14) . This is to our knowledge the first time that disruption of PKCa signaling has been specifically linked to the induction of B-CLL. Our studies show that the ability to induce the development of B-CLL in HPCs only occurs on PKCa but not PKCy or PKCs ubversion, suggesting that this may be a unique property of PKCa. PKC-mediated signaling pathways have been implicated previously in the maintenance of B-CLL cell survival as PKC inhibitors, and in some cases classic PKC inhibitors, are effective at inducing apoptosis of B-CLL cells, but the role of individual PKC isoforms has not been elucidated (3, 6, 43) . At first sight, therefore, these studies seem to be at odds with our findings as we have clearly shown that the PKCa-KR-expressing B-CLL-like cells generated in our coculture system display a reduction in PKC activity and may indeed occur as a consequence of specifically targeting PKCa activity. However, this apparent discrepancy may simply reflect that we have used an established dominant-negative PKCa construct as opposed to using inhibitors that, at best, selectively inhibit classic PKC isoforms. Thus, these inhibitors might perhaps be targeting other PKC isoforms; alternatively, PKCh and/or PKCg could play a role dominant to that of PKCa in promoting B-CLL survival. Of note, PKCa and, more recently, Btk have been shown to function as adapter proteins in a manner that is independent of their kinase activity to transduce intracellular signals (44) (45) (46) (47) , suggesting that blocking the oncogenic property of PKCa is more complex than simply inhibiting its kinase activity. In conclusion, our studies reveal an important link between the subversion of PKCa signaling and the induction of B-CLL and have uncovered a potentially important avenue for developing drug therapies to treat of B-CLL. 
